Nektar commences dosing in NKTR-192 Phase 1 clinical study for treatment of acute pai
Nektar Therapeutics announced today that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the pharmacokinetics and safety of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate.